AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere,…
| Quarter | Revenue | YoY | Net Income | EPS (dil.) | YoY | Gross Margin | Op. Margin |
|---|---|---|---|---|---|---|---|
| Q1 2026 Mar 2026 | $15.29B | +12.5% | $3.08B | $1.97 | +5.3% | 82.5% | 27.8% |
| Q4 2025 Dec 2025 | $15.50B | — | $2.33B | $1.49 | +55.2% | 79.9% | 19.2% |
| Q3 2025 Sep 2025 | $15.19B | — | $2.53B | — | — | 81.6% | 23.6% |
| Q2 2025 Jun 2025 | $14.46B | — | $2.45B | $1.57 | — | 82.9% | 24.3% |
| Q1 2025 Mar 2025 | $13.59B | — | $2.92B | $1.87 | — | 83.5% | 27.0% |
Data from Yahoo Finance. YoY compares the same quarter of the prior fiscal year.
Can AstraZeneca contain the damage after the AstraZeneca Wainua Trial miss erased billions in market value in a single session? Maik Kemper Editor in Chief Although the trial…